Delhi-based pharmaceutical company Mankind Pharma has signed a pact with the Russian Direct Investment Fund (RDIF) for the marketing and distribution of Russia’s Sputnik V vaccine.
RDIF has reached agreements with the Indian pharma company to produce 300 million doses of vaccine.
Earlier in September, RDIF entered into a partnership with Dr. Reddy’s Laboratories to conduct human clinical trials of the Sputnik V vaccine in India. Under the partnership, RDIF will initially supply 100 million doses to the laboratory company.
On Saturday, Dr. Reddy’s laboratories got approval from the Drug Control General of India (DCGI) to conduct phase 2 and phase 3 clinical human trials for the Russian-based vaccine.
The vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world’s first registered COVID-19 vaccine.
Sputnik V is undergoing phase 3 clinical trials in Russia which will involve 40,000 participants. Meanwhile, 16000 people have already received the first dose of the two-shot vaccine.
